New study tests 2-Year dupilumab treatment for Kids' eczema

NCT ID NCT05983068

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at how well dupilumab (Dupixent) works over two years in about 48 children aged 6 to 14 with moderate-to-severe eczema. The main goal is to see if the drug improves the skin's barrier function, measured by water loss through the skin. All participants receive dupilumab, and the study tracks safety and skin changes over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dupilumab (Dupixent)
What this could lead to: If successful, this could show that long-term dupilumab use improves skin barrier function in children with eczema, supporting its continued use for disease control.
What could go wrong: This is a small, open-label study with no placebo group, so results may not be definitive. Side effects like injection reactions or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATITIS ATOPIC

Contacts and locations

Locations

Investigational Site Number : 8260001

Sheffield, S10 2TH, United Kingdom
NYU Langone Medical Center- Site Number : 8400004

New York, New York, 10016, United States
National Jewish Health Medical Center- Site Number : 8400001

Denver, Colorado, 80206, United States
SSM Health Saint Louis University Hospital- Site Number : 8400006

St Louis, Missouri, 63104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.